Knight Therapeutics Inc (CVE:GUD) had its price target reduced by investment analysts at National Bank Financial from C$10.75 to C$10.50 in a report released on Monday. The brokerage currently has an “outperform” rating on the specialty pharmaceutical company’s stock. National Bank Financial’s price objective would suggest a potential upside of 71.01% from the company’s current price.

Shares of Knight Therapeutics (CVE:GUD) remained flat at $C$6.14 during trading on Monday. Knight Therapeutics has a 1 year low of C$3.51 and a 1 year high of C$7.24.

COPYRIGHT VIOLATION WARNING: “Knight Therapeutics Inc (GUD) Price Target Cut to C$10.50 by Analysts at National Bank Financial” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/knight-therapeutics-inc-gud-price-target-cut-to-c10-50-by-analysts-at-national-bank-financial/1700838.html.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company’s commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement.

Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.